News

XtalPi and Pierre Fabre join forces on AI-powered drug discovery

What's the deal? On 9 November 2026, Hong Kong-listed XtalPi and French pharmaceutical group Laboratoires Pierre Fabre announced a research and development collaboration to discover new small-molecule medicines. XtalPi will use its integrated AI and robotics platform to design and deliver novel drug candidates against undisclosed targets in oncology, and potentially in dermatology and rare diseases. Pierre Fabre will contribute its disease biology and clinical development expertise, select the most promising compounds, and lead their clinical and commercial development. The agreement includes an upfront payment, milestone payments and downstream economic participation; specific financial terms were not disclosed.

Why it matters: The deal pairs XtalPi's approach — combining quantum-physics-based calculation, AI models and automated laboratories to design molecules from scratch — with a mid-sized pharma expanding its oncology research. XtalPi, founded in 2015 by three MIT-trained physicists, has built a series of discovery collaborations with pharmaceutical partners, including a collaboration with DoveTree Medicines that started with a $51 million upfront payment. For Pierre Fabre, whose pharmaceutical R&D spend rose 14% in 2025, the agreement adds AI-powered discovery capacity as it targets historically hard-to-drug proteins — an area of significant unmet medical need. Both companies say the collaboration focuses on challenging targets where conventional chemistry has struggled, and aim to accelerate the identification of clinical candidates across multiple research programmes.

Read more: Laboratoires Pierre Fabre, 9 November 2026

More top stories